Other equities analysts have also recently issued reports about the stock. Noble Financial reaffirmed a buy rating on shares of Anavex Life Sciences in a report on Tuesday, December 12th. ValuEngine cut shares of Anavex Life Sciences from a hold rating to a sell rating in a report on Tuesday, November 21st.
Anavex Life Sciences (AVXL) traded up $0.02 during mid-day trading on Wednesday, reaching $2.56. 223,100 shares of the company’s stock were exchanged, compared to its average volume of 323,922. Anavex Life Sciences has a 12 month low of $2.45 and a 12 month high of $6.49. The firm has a market capitalization of $113.22, a PE ratio of -7.65 and a beta of 0.89.
Several institutional investors have recently made changes to their positions in AVXL. Millennium Management LLC increased its holdings in shares of Anavex Life Sciences by 95.2% in the 4th quarter. Millennium Management LLC now owns 44,895 shares of the biotechnology company’s stock valued at $145,000 after acquiring an additional 21,895 shares during the period. Alliancebernstein L.P. acquired a new position in shares of Anavex Life Sciences in the 2nd quarter valued at $158,000. The Manufacturers Life Insurance Company increased its holdings in shares of Anavex Life Sciences by 37.7% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 31,876 shares of the biotechnology company’s stock valued at $169,000 after acquiring an additional 8,728 shares during the period. Virtu KCG Holdings LLC purchased a new position in Anavex Life Sciences in the 2nd quarter valued at $186,000. Finally, Wells Fargo & Company MN grew its position in Anavex Life Sciences by 12.1% in the 2nd quarter. Wells Fargo & Company MN now owns 40,385 shares of the biotechnology company’s stock valued at $215,000 after buying an additional 4,347 shares during the last quarter. 22.63% of the stock is currently owned by institutional investors and hedge funds.
About Anavex Life Sciences
Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer’s disease and other central nervous system (CNS) diseases.
Receive News & Ratings for Anavex Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.